LENSAR, Inc. (LNSR): Price and Financial Metrics
GET POWR RATINGS... FREE!
LNSR Stock Summary
- LNSR has a market capitalization of $39,573,661 -- more than approximately only 11.35% of US stocks.
- LNSR's went public 2.16 years ago, making it older than merely 11.2% of listed US stocks we're tracking.
- The ratio of debt to operating expenses for LENSAR INC is higher than it is for about only 12.95% of US stocks.
- If you're looking for stocks that are quantitatively similar to LENSAR INC, a group of peers worth examining would be ASTC, NTRA, DMRC, VMEO, and WISH.
- To dig deeper into the stock's financial statements, go to LNSR's page on browse-edgar?action=getcompany&CIK=0001320350.
LNSR Valuation Summary
- LNSR's price/sales ratio is 1.1; this is 77.08% lower than that of the median Healthcare stock.
- Over the past 26 months, LNSR's EV/EBIT ratio has gone up 8.6.
Below are key valuation metrics over time for LNSR.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| LNSR | 2022-11-25 | 1.1 | 0.9 | -1.8 | -1.0 |
| LNSR | 2022-11-23 | 1.1 | 0.9 | -1.8 | -1.1 |
| LNSR | 2022-11-22 | 1.1 | 0.9 | -1.9 | -1.1 |
| LNSR | 2022-11-21 | 1.1 | 1.0 | -1.9 | -1.1 |
| LNSR | 2022-11-18 | 1.3 | 1.1 | -2.2 | -1.4 |
| LNSR | 2022-11-17 | 1.2 | 1.1 | -2.1 | -1.4 |
LNSR Price Target
For more insight on analysts targets of LNSR, see our LNSR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $20.00 | Average Broker Recommendation | 1 (Strong Buy) |
LNSR Stock Price Chart Interactive Chart >
LNSR Price/Volume Stats
| Current price | $3.32 | 52-week high | $8.80 |
| Prev. close | $3.59 | 52-week low | $3.26 |
| Day low | $3.26 | Volume | 17,100 |
| Day high | $3.60 | Avg. volume | 11,816 |
| 50-day MA | $4.95 | Dividend yield | N/A |
| 200-day MA | $6.15 | Market Cap | 36.60M |
LENSAR, Inc. (LNSR) Company Bio
LENSAR, Inc. develops laser technologies. The Company provides autoprecision laser and proprietary 3-D imaging, measurement, and guidance system for refractive cataract surgery. LENSAR serves the healthcare industries throughout the United States.
Latest LNSR News From Around the Web
Below are the latest news stories about LENSAR INC that investors may wish to consider to help them evaluate LNSR as an investment opportunity.
LENSAR to Present at Two Upcoming Investor ConferencesORLANDO, Fla., November 22, 2022--LENSAR, Inc. (NASDAQ: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced Nick Curtis, Chief Executive Officer will present at two upcoming investor conferences: |
Analysts Offer Insights on Healthcare Companies: LENSAR (LNSR) and Cerevel Therapeutics Holdings (CERE)Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on LENSAR (LNSR – Research Report) and Cerevel Therapeutics Holdings (CERE – Research Report). LENSAR (LNSR) BTIG analyst Ryan Zimmerman maintained a Buy rating on LENSAR today and set a price target of $14.00. The company's shares closed last Wednesday at $4.35. According to TipRanks. |
LENSAR Reports Third Quarter 2022 Financial Results and Provides Business UpdateORLANDO, Fla., November 09, 2022--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter ended September 30, 2022 and provided a business update. |
LENSAR to Report Third Quarter 2022 Financial Results on Wednesday, November 9, 2022ORLANDO, Fla., November 02, 2022--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s third quarter 2022 financial results will be released before market open on Wednesday, November 9, 2022. LENSAR’s management will host a conference call and webcast at 8:30 am ET on Wednesday, November 9, 2022 to discuss the financial results and re |
LENSAR Announces Application for Certification of the ALLY™ Adaptive Cataract Treatment System in the EUORLANDO, Fla., September 08, 2022--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced the application for certification of the ALLY™ Adaptive Cataract Treatment System ("ALLY" or the "ALLY System") in the European Union. |
LNSR Price Returns
| 1-mo | -30.25% |
| 3-mo | -41.13% |
| 6-mo | -48.13% |
| 1-year | -51.32% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -44.57% |
| 2021 | -17.38% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...